Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients

Uppsala University

Status: Unknown

Conditions: Acute Coronary Syndrome; Myocardial Infarction

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01623700

U-11-001

Details and patient eligibility

About

This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are merged into The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART).

The aim of this study is to investigate the impact of different antithrombotic treatment options (treatment duration, type of treatment and combination of treatments) in Acute Coronary Syndrome (ACS) patients on outcomes such as recurrent ischemic events and mortality.

Enrollment: 78,000 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with an event of ACS under the study period
• Patient found in the National Registry of Drug Prescriptions and treated or not treated with antithrombotic drug/s (acetylsalicylic acid and/or either clopidogrel/ticlopidine/prasugrel and/or warfarin)

Exclusion criteria

• Patients will not be excluded from the database if they fulfill inclusion criteria.

Trial design

78,000 participants in 3 patient groups

dual antiplatelet treatment 12 months after ACS event

dual antiplatelet treatment 6 months after ACS event

dual antiplatelet treatment 3 months after ACS event